2022
DOI: 10.1080/00365521.2022.2041084
|View full text |Cite
|
Sign up to set email alerts
|

Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 39 publications
0
2
0
Order By: Relevance
“…The secretion of glucagon-like peptide 1 (GLP-1) by L cells, expression of the surface receptor TGR5 by intestinal L cells, and induction of GLP-1 release from enteroendocrine cells by the TGR5 agonist 6α-ethyl-23(S)-methylcholic acid (EMCA, INT-777) inhibits glucagon secretion and gastric emptying and suppresses food uptake (Thomas et al, 2009 ). One study demonstrated that the glucagon-like peptide-1 receptor agonist ROSE-010 reduced pain during IBS episodes (Touny et al, 2022 ). However, GLP-1 acts on the enteric nervous system by reducing excitatory cholinergic neurotransmitters and regulating nitric oxide release through presynaptic GLP-1Rs (Amato et al, 2010 ).…”
Section: Endocrine System Abnormalitiesmentioning
confidence: 99%
“…The secretion of glucagon-like peptide 1 (GLP-1) by L cells, expression of the surface receptor TGR5 by intestinal L cells, and induction of GLP-1 release from enteroendocrine cells by the TGR5 agonist 6α-ethyl-23(S)-methylcholic acid (EMCA, INT-777) inhibits glucagon secretion and gastric emptying and suppresses food uptake (Thomas et al, 2009 ). One study demonstrated that the glucagon-like peptide-1 receptor agonist ROSE-010 reduced pain during IBS episodes (Touny et al, 2022 ). However, GLP-1 acts on the enteric nervous system by reducing excitatory cholinergic neurotransmitters and regulating nitric oxide release through presynaptic GLP-1Rs (Amato et al, 2010 ).…”
Section: Endocrine System Abnormalitiesmentioning
confidence: 99%
“…In animal models, a GLP1 analogue or GLP1R agonist improved the visceral pain hypersensitivity in rats [ 110 , 111 ]. New evidence in clinical trials has shown that the subcutaneous injection of a GLP1 analogue, ROSE-010, decreased pain hypersensitivity [ 112 , 113 ]. Although these exogenous peptide treatment data strongly support the connection between GLP1 and visceral pain, less research has been performed to understand the effects of endogenous EECs-derived GLP1 in mediating visceral pain.…”
Section: Enteroendocrine Cells In Visceral Pain and Neuropathic Painmentioning
confidence: 99%